24 April 2014 | News | By BioSpectrum Bureau
Australian Biotech major Prima BioMed is said to have extended its clinical trials on CVacâ„¢
Singapore: Prima BioMed, Australia's leading biotechnology company pioneering in therapeutic area of cancer is said to be extending clinical trials of CVacTM.
On Monday, the company is said to have made the decision to extend the clinical trials of CVacTM, which is its flagship product candidate
The company's shares are in a trading hald, pending the announcement that is said to be made on June 26, Wednesday.